{"id":"NCT01684878","sponsor":"Hoffmann-La Roche","briefTitle":"Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)","officialTitle":"A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-22","primaryCompletion":"2015-01-30","completion":"2016-04-28","firstPosted":"2012-09-13","resultsPosted":"2016-11-23","lastUpdate":"2017-05-23"},"enrollment":208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer"],"interventions":[{"type":"DRUG","name":"Gemcitabine (Chemotherapy)","otherNames":[]},{"type":"DRUG","name":"Paclitaxel (Chemotherapy)","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Topotecan (Chemotherapy)","otherNames":[]}],"arms":[{"label":"Part 1: Pertuzumab + Topotecan","type":"EXPERIMENTAL"},{"label":"Part 1: Pertuzumab + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Part 2: Pertuzumab+Chemotherapy","type":"EXPERIMENTAL"},{"label":"Part 2: Placebo+Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer. In the non-randomized Part 1 safety run-in, participants will receive pertuzumab plus either topotecan or paclitaxel. In the randomized, double-blind Part 2 of the study, participants will receive either pertuzumab or placebo in combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).","primaryOutcome":{"measure":"Part 1: Percentage of Participants With Adverse Events (AEs)","timeFrame":"Approximately 28 months (assessed at screening, baseline until 28 days after the last dose of study treatment)","effectByArm":[{"arm":"Part 1: Pertuzumab + Topotecan","deltaMin":95.5,"sd":null},{"arm":"Part 1: Pertuzumab + Paclitaxel","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":68,"countries":["Austria","Belgium","Denmark","France","Germany","Italy","Netherlands","Norway","Spain","Sweden"]},"refs":{"pmids":["31420414"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":22},"commonTop":["Diarrhoea","Nausea","Anaemia","Asthenia","Vomiting"]}}